Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Precautions Needed for Infections in Treating RA with Actemra: PMS Data
December 15, 2008
- 2 Combinations of ARB and Diuretic Recommended for Approval
December 15, 2008
- Gov't to Relax Belt-Tightening Fiscal Policy
December 15, 2008
- REGULATORY NEWS IN BRIEF
December 15, 2008
- Research on Biomarkers Essential to Develop Anticancer Drugs: Dr Inoue
December 15, 2008
- Pfizer to Break Dependence on Blockbusters: Mr Iwasaki
December 15, 2008
- Tripartite Collaboration Needed to Bring Benefits of iPS Cells to Patients: Prof. Yamanaka
December 15, 2008
- Points to Remember in Developing Drugs for OAB Outlined by Former PMDA Reviewer
December 15, 2008
- Clarification of Diabetes-Related Genes Will Benefit Asians as a Whole
December 15, 2008
- PMDA to Create New Organization to Handle Int'l Affairs
December 15, 2008
- R&D NEWS IN BRIEF
December 15, 2008
- Korosho Starts Discussions on Distribution of Medical Devices
December 15, 2008
- Freedom from Fear in 2009
December 15, 2008
- PDA Closure Set from Japan Lifeline Recommended for Approval
December 15, 2008
- Chugai, Chiome Sign Agreement on Monoclonal Antibody Production
December 15, 2008
- SELF-MEDICATION NEWS IN BRIEF
December 15, 2008
- BUSINESS NEWS IN BRIEF
December 15, 2008
- SURVEY／Diabetes Is Most Commonly Examined
December 15, 2008
- Wholesalers Should Talk with Manufacturers on Equal Footing: Mr Negi
December 15, 2008
- JSMO to Prepare GL for KRAS Gene Mutation Testing
December 15, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…